OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board

SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Holbrook Kohrt, M.D., Ph.D., to the company’s Scientific Advisory Board. Dr. Kohrt joins a growing panel of distinguished experts and renowned thought leaders, and will contribute his considerable expertise to the company as it works to advance an expanding immuno-oncology pipeline.

Holbrook E. Kohrt, M.D., Ph.D., is an Assistant Professor at Stanford Cancer Institute, and currently investigates novel therapeutic strategies to enhance anti-tumor immunity. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar, and American Society of Hematology Research Fellow. During this time he developed, validated, and nationally implemented a nomogram for risk prediction in early stage breast cancer.

Dr. Kohrt trained in Internal Medicine at Stanford University through the Clinical Investigator Pathway and completed fellowship in Hematology and Oncology at Stanford with a research focus on preclinical models of novel immunomodulatory antibodies. He received his Ph.D. in clinical trial design and tumor immunology from Stanford. Most notably, Dr. Kohrt along with Dr. Ron Levy at Stanford have been the academic leaders in the advancement of intratumoral immuno-oncology therapies. Recently, they conducted a Phase I/II clinical trial using CG-enriched oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9) in non-Hodgkin’s lymphoma. As well, they have demonstrated that intratumoral administration of the checkpoint inhibitor, anti-CTLA-4 antibody, is a safe and effective route of therapy in mice, demonstrating both local and systemic responses.

“We are extremely excited to have Dr. Kohrt join our scientific advisory board”, said Punit Dhillon, President and CEO. “Holbrook’s background and experience will be invaluable as we not only move our ImmunoPulse program forward into later stage clinical development, but he and the rest of the SAB, will also be integral in keeping our intratumoral immunotherapy platform at the cutting edge of scientific advances.”

Dr. Kohrt said, “OncoSec’s DNA-based intratumoral immunotherapy technology has the potential to address an important unmet medical need in cancer immunotherapy. I am pleased to help guide OncoSec’s scientific team as it continues to target difficult diseases and advance new intratumoral therapeutic targets for the treatment of cancer.”

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

OncoSec Medical Inc.
Investor Relations:
Veronica Vallejo, CFO

Source: OncoSec Medical Inc.